Hong Kong Li's pharmaceutical company acquires the rights and interests of the new generation of warfarin analogue, techfarin China

Warfarin is an old drug for more than 60 years, but it has been the main drug of atrial fibrillation until the new anticoagulant appeared recently However, the drug drug drug interaction of warfarin is complex, individual differences are huge, affected by eating, so it is very inconvenient to use, so it is necessary to monitor the coagulation index INR Tecarfarin is to solve these inconvenient problems Tecarfarin is very clever This compound has an ester group, which is broken down by an ester hydrolase and becomes inactive Therefore, techfarin does not rely on liver metabolism, has no drug interaction problems, and does not need to monitor INR Renal dysfunction does not affect its clearance, so theoretically it is applicable to a large population This so-called reverse metabolic drug design concept is actually very interesting, especially in improving drugs through kidney metabolism Because esterase is everywhere, drugs that can't be used by patients with renal dysfunction can be extended to this considerable population if they are transformed according to this idea Tecarfarin was developed by axys in the 1990s, but later failed to show an advantage in the head-to-head clinical trial with warfarin As a result, investors did not buy the concept of reverse metabolism, and axys went bankrupt Several senior executives of the company set up armetheon and continued to develop techfarin According to armetheon, the failure to beat warfarin was due to the fact that the advantages of techfarin in highly monitored clinical trials could not be shown, and the problem of using warfarin in the real world would be highlighted The third phase of armetheon's clinical practice began last year After serious side effects of dabigatran, a new anticoagulant of Bi, in patients with cardiac stents, techfarin seems to have found a real place to specialize in this particular population At present, tecarfarin has the advantage of vitamin K as an antidote However, once the new anticoagulant appears bleeding, it has not yet reversed the antidote However, several antidotes have shown efficacy in the third phase of clinical treatment Li's big pharmaceutical company has recently been buying some relatively cheap assets Three years ago, it purchased the ophthalmic drug thymosin beta 4 series of regenerx, which was on the verge of bankruptcy Although tearfarin may be used for stroke prevention, there is little chance to significantly surpass warfarin, so the purchase price will not be very expensive